Neurometrix Inc (NASDAQ:NURO) Shorted Shares Decreased By 6.53%

NeuroMetrix, Inc. (NASDAQ:NURO) Corporate Logo Neurometrix Inc (NASDAQ:NURO) had a decrease of its short interest by 6.53%. In February was announced NURO’s total 260,500 short interest by FINRA. The down change of 6.53% from 278,700 shares was reported. 4 days will cost NURO with 71,200 average volume to recover its former position.

Ticker’s shares touched $0.9011 during the last trading session after 2.05% change.NeuroMetrix, Inc. has volume of 20,257 shares. Since February 6, 2018 NURO has declined 43.71% and is downtrending. The stock underperformed the S&P500 by 43.71%.

NeuroMetrix, Inc., a medical device company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders.The company has $6.92 million market cap. The firm develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes.450.55 is the P/E ratio. The Company’s marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; the SENSUS pain therapy device, a prescription neurostimulation device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; and ADVANCE NCS/EMG system, a platform for the performance of traditional nerve conduction studies.

For more NeuroMetrix, Inc. (NASDAQ:NURO) news brought out briefly go to: , , , or . The titles are as follows: “Kroger Co. Q3 adjusted earnings Beat Estimates – Nasdaq” brought out on December 06, 2018, “NeuroMetrix Reports Q4 and Full Year 2017 Financial Results – GlobeNewswire” on January 25, 2018, “Quell Named CES 2019 Innovation Awards Honoree Nasdaq:NURO – GlobeNewswire” with a publish date: January 08, 2019, “Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan – Benzinga” and the last “The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas – Benzinga” with publication date: December 19, 2018.

Click Here to Continue...

Add a Comment

Your email address will not be published. Required fields are marked *